Literature DB >> 19191640

Detection of circulating Chlamydophila pneumoniae in patients with coronary artery disease and healthy control subjects.

Sarah Klizas West1, Sue J Kohlhepp, Ruyun Jin, Curt A Gleaves, Walter Stamm, David N Gilbert.   

Abstract

BACKGROUND: There is a long history of research suggesting that Chlamydophila pneumoniae is associated with coronary artery disease (CAD). C. pneumoniae in peripheral blood mononuclear cells (PBMCs) could serve as a risk factor for CAD if respiratory infection with C. pneumoniae spreads to atherosclerotic plaques through PBMCs or if infected plaques shed C. pneumoniae-laden PBMCs into the circulation.
METHODS: PBMCs were collected from 86 case patients with abnormal coronary angiogram findings and from 91 age- and gender-matched healthy control subjects. The healthy control subjects were strictly defined as not having atherosclerosis on the basis of absence of both clinical atherosclerotic disease and traditional risk factors for CAD. PBMCs were probed for the presence of C. pneumoniae nucleic acid by 2 separate real-time polymerase chain reaction (PCR) assays that used primers for outer membrane protein A (ompA) and 16S ribosomal RNA. C. pneumoniae serologic findings were determined for both case patients and control subjects.
RESULTS: Despite serologic findings indicating past exposure to C. pneumoniae (immunoglobulin G titer, >or=1:16) in 74% of case patients with CAD and control subjects, no C. pneumoniae DNA or RNA was detected in PBMCs from any of the case patients or control subjects, including a subset of 42 participants (18 with CAD) who had samples obtained serially over 8 months. Multiple laboratory controls, including controls for inhibition of PCR, produced expected results.
CONCLUSIONS: The uniformly negative results with use of highly sensitive methods are in contrast to much of the published literature. Probing of PBMCs for the genes of C. pneumoniae does not appear useful as a noninvasive way of detecting the presence of C. pneumoniae in atheromatous lesions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191640     DOI: 10.1086/596710

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

Review 1.  Antibiotic resistance in Chlamydiae.

Authors:  Kelsi M Sandoz; Daniel D Rockey
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

2.  Analysis of Chlamydia pneumoniae infection in mononuclear cells by reverse transcription-PCR targeted to chlamydial gene transcripts.

Authors:  Laura Mannonen; Eveliina Markkula; Mirja Puolakkainen
Journal:  Med Microbiol Immunol       Date:  2011-01-30       Impact factor: 3.402

3.  Bacterial infections are associated with cardiovascular disease in Iran: a meta-analysis.

Authors:  Farzad Khademi; Hamid Vaez; Amir Abbas Momtazi-Borojeni; Araz Majnooni; Maciej Banach; Amirhossein Sahebkar
Journal:  Arch Med Sci       Date:  2019-06-19       Impact factor: 3.318

4.  Is there any relationship between Chlamydophila pneumoniae and coronary atherosclerosis among Iranians?

Authors:  Mohammad Hadi Sadeghian; Seyed Abbas Tabatabaee Yazdi; Hossein Ayatollahi; Mohammad Reza Keramati; Kiarash Ghazvini; Ali Reza Rezai; Nasrin Heidari; Maryam Sheikhi; Gohar Shaghayegh
Journal:  Niger Med J       Date:  2013-01

5.  Immunization of Chlamydia pneumoniae (Cpn)-infected Apob(tm2Sgy)Ldlr(tm1Her)/J mice with a combined peptide of Cpn significantly reduces atherosclerotic lesion development.

Authors:  Min Xia; Daxin Chen; Valeria Endresz; Ildiko Faludi; Andrea Szabo; Eva Gonczol; Vijay Kakkar; Xinjie Lu
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

6.  Association of Chlamydia pneumoniae Infection With Atherosclerotic Plaque Formation.

Authors:  Omid Assar; Azim Nejatizadeh; Farzaneh Dehghan; Mohammad Kargar; Nader Zolghadri
Journal:  Glob J Health Sci       Date:  2015-09-28

7.  Presence of Chlamydophila pneumoniae DNA in blood cells is a frequent event in patients with the late stage of primary cutaneous lymphomas and with atopic dermatitis.

Authors:  Bogusław Nedoszytko; Piotr Wierzbicki; Leena Karenko; Agata Maciejewska-Radomska; Przemysław Stachewicz; Monika Zabłotna; Jolanta Gleń; Liisa Väkevä; Roman J Nowicki; Małgorzata Sokołowska-Wojdyło
Journal:  Postepy Dermatol Alergol       Date:  2018-06-18       Impact factor: 1.837

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.